
May 15 (Reuters) - Biofrontera Inc BFRI.O:
BIOFRONTERA INC. ANNOUNCES NEW PATENT PROTECTION ON AMELUZ® UNTIL 2043 AND THE COMPLETION OF PATIENT ENROLLMENT IN PHASE 2B STUDY OF AMELUZ® (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS
BIOFRONTERA INC - EXPECTS LAST-PATIENT-OUT IN Q3 2025 FOR AMELUZ TRIAL